JP7445609B2 - Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途 - Google Patents

Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途 Download PDF

Info

Publication number
JP7445609B2
JP7445609B2 JP2020568471A JP2020568471A JP7445609B2 JP 7445609 B2 JP7445609 B2 JP 7445609B2 JP 2020568471 A JP2020568471 A JP 2020568471A JP 2020568471 A JP2020568471 A JP 2020568471A JP 7445609 B2 JP7445609 B2 JP 7445609B2
Authority
JP
Japan
Prior art keywords
group
formula
aryl
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527071A (ja
JP2021527071A5 (https=
Inventor
ブロンドー，ジャン－ポール
コルチア，アントニオ
ローデット，マリオン
ルズーアオ，フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Saclay
Universite de Toulouse
Universita degli Studi di Roma La Sapienza
Original Assignee
Universite Toulouse III Paul Sabatier
Universite Paris Saclay
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier, Universite Paris Saclay, Universita degli Studi di Roma La Sapienza filed Critical Universite Toulouse III Paul Sabatier
Publication of JP2021527071A publication Critical patent/JP2021527071A/ja
Publication of JP2021527071A5 publication Critical patent/JP2021527071A5/ja
Application granted granted Critical
Publication of JP7445609B2 publication Critical patent/JP7445609B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020568471A 2018-06-06 2019-06-06 Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途 Active JP7445609B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305685 2018-06-06
EP18305685.2 2018-06-06
PCT/EP2019/064886 WO2019234197A1 (en) 2018-06-06 2019-06-06 Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses

Publications (3)

Publication Number Publication Date
JP2021527071A JP2021527071A (ja) 2021-10-11
JP2021527071A5 JP2021527071A5 (https=) 2023-11-16
JP7445609B2 true JP7445609B2 (ja) 2024-03-07

Family

ID=62715982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568471A Active JP7445609B2 (ja) 2018-06-06 2019-06-06 Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途

Country Status (6)

Country Link
US (1) US20210230179A1 (https=)
EP (1) EP3801511A1 (https=)
JP (1) JP7445609B2 (https=)
KR (1) KR20210057704A (https=)
CN (1) CN112638382B (https=)
WO (1) WO2019234197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072547A1 (en) * 2019-12-13 2022-10-19 Institut National De La Sante Et De La Recherche Medicale - Inserm Epac1 inhibitors for the treatment of idiopathic pulmonary fibrosis
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530816A (ja) 2002-06-06 2005-10-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換３−アミノ−チエノ［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物、その製造方法及び使用
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
WO2014053315A1 (en) 2012-10-02 2014-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tetrahydroquinoline derivatives and their use as epac inhibitors
JP2016501883A (ja) 2012-12-07 2016-01-21 シガ テクノロジーズ，インコーポレーテッド デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体
JP2016537328A (ja) 2013-10-15 2016-12-01 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077250A1 (en) * 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530816A (ja) 2002-06-06 2005-10-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換３−アミノ−チエノ［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物、その製造方法及び使用
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
WO2014053315A1 (en) 2012-10-02 2014-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tetrahydroquinoline derivatives and their use as epac inhibitors
JP2016501883A (ja) 2012-12-07 2016-01-21 シガ テクノロジーズ，インコーポレーテッド デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体
JP2016537328A (ja) 2013-10-15 2016-12-01 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Also Published As

Publication number Publication date
EP3801511A1 (en) 2021-04-14
JP2021527071A (ja) 2021-10-11
US20210230179A1 (en) 2021-07-29
CN112638382B (zh) 2024-10-18
CN112638382A (zh) 2021-04-09
KR20210057704A (ko) 2021-05-21
WO2019234197A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP6660993B2 (ja) デオキシウリジントリホスファターゼ阻害剤
JP6513095B2 (ja) ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
JP2022068335A (ja) 黒色腫の治療のための組合せ医薬
US10544105B2 (en) Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US20200325105A1 (en) Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
JP7445609B2 (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途
BRPI0807928A2 (pt) Métodos para identificar um ativador de lyn quinase, e para tratar diabetes em um humano, kit, e, composição
JP2023528945A (ja) Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤、並びに医薬における、がんの予防及び治療における、その使用
US11447469B2 (en) Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof
WO2023105008A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
EP2903612B1 (en) Tetrahydroquinoline derivatives and their use as epac inhibitors
WO2024121437A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231030

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240226

R150 Certificate of patent or registration of utility model

Ref document number: 7445609

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150